Abstract Number: 1720 • 2013 ACR/ARHP Annual Meeting
Risk Of Cardiovascular Disease and Use Of Xanthine Oxidase Inhibitors For Gout
Background/Purpose: Hyperuricemia and gout are associated with an increased risk of hypertension and cardiovascular disease (CVD) such as myocardial infarction (MI) and stroke. Xanthine oxidase…Abstract Number: 1721 • 2013 ACR/ARHP Annual Meeting
A Prediction Tool for Incident Gout Among Those With Hyperuricemia
Background/Purpose: The most common form of inflammatory arthritis observed in men is gout, a condition characterized by hyperuricemia and deposition of uric acid crystals in…Abstract Number: 1722 • 2013 ACR/ARHP Annual Meeting
Does Starting Allopurinol Prolong Acute Treated Gout?
Background/Purpose: Gout is a common cause of morbidity in the US population. Traditionally, allopurinol is not initiated during an acute episode to avoid prolonging…Abstract Number: 1724 • 2013 ACR/ARHP Annual Meeting
The Role Of Low-Grade Inflammation In The Association Between Uric Acid and Atherosclerosis: The Codam Study
Background/Purpose: Uric acid may be involved in the atherosclerotic process by increasing the level of low-grade inflammation. The aims of this study were: 1) to…Abstract Number: 1726 • 2013 ACR/ARHP Annual Meeting
Survivin Inhibition Disturbs Bcl-6 and Blimp-1 Control Of Lymphocyte Maturation and Alleviates Antigen-Induced Arthritis
Background/Purpose: Survivin is a proto-oncogene known to regulate cell division and apoptosis. In patients with rheumatoid arthritis, survivin has emerged as an independent predictor of…Abstract Number: 1727 • 2013 ACR/ARHP Annual Meeting
Novel Selective Inhibitors Of Nuclear Export Attenuate Inflammation and Prevent Bone Mineral Density Loss In Multiple Preclinical Models Of Rheumatoid Arthritis
Background/Purpose: Exportin 1 (XPO1; also called chromosome region maintenance 1, CRM1) is a key protein that controls the export of ~220 cargo proteins and several…Abstract Number: 1688 • 2013 ACR/ARHP Annual Meeting
Does The Treatment With Anti-Coagulants and Anti-Platelets Protect Giant Cell Arteritis Patients From Visual Manifestations?
Background/Purpose: Visual manifestations such as diplopia, amaurosis fugax or blindness occur in up to half of the giant cell arteritis (GCA) patients. Some studies have…Abstract Number: 1689 • 2013 ACR/ARHP Annual Meeting
Antiplatelet Agents Decrease Ischemic Complications In Systemic Large Vessel Vasculitides: A Meta-Analysis
Background/Purpose: Large Vessel Vasculitides (LVV) consist of Giant Cell Arteritis and Takayasu’s Arteritis, which are chronic systemic autoimmune diseases characterized by inflammation of large blood…Abstract Number: 1685 • 2013 ACR/ARHP Annual Meeting
Long-Term Use Of Tocilizumab For The Treatment Of Giant Cell Arteritis
Background/Purpose: A sizeable percentage of giant cell arteritis (GCA) patients experience disease relapse upon glucocorticoid (GC) tapering, and a clearly effective GC-sparing alternative has not…Abstract Number: 1686 • 2013 ACR/ARHP Annual Meeting
Tocilizumab In Refractory Takayasu Arteritis: a Case Series and Updated Literature Review.²
Tocilizumab in refractory Takayasu arteritis: a case series and updated literature review.Background/Purpose: The aim of this study is to analyze the efficacy and tolerance of…Abstract Number: 1687 • 2013 ACR/ARHP Annual Meeting
Tocilizumab In Refractory Aortitis: A Multicenter Study Of 13 Patients
Background/Purpose: Aortitis can occur alone or associated with other conditions. It is often refractory to standard immunosuppressive therapy. IL-6 has been implicated in the mechanisms…Abstract Number: 1690 • 2013 ACR/ARHP Annual Meeting
Impaired Vitamin D Receptor Signaling Upregulates Transforming Growth Factor Beta (TGFβ) Signaling In Systemic Sclerosis
Background/Purpose: Vitamin D receptor (VDR) is a member of the nuclear receptor superfamily. Its ligand, 1,25-(OH)2D, is a metabolically active hormone derived from vitamin D3.…Abstract Number: 1691 • 2013 ACR/ARHP Annual Meeting
The STAT1 Signaling Pathway In Giant Cell Arteritis
Background/Purpose: In giant cell arteritis (GCA), CD4 T cells, macrophages and multinucleated giant cells form granulomatous lesions in the walls of medium and large arteries.…Abstract Number: 1692 • 2013 ACR/ARHP Annual Meeting
Characterization Of Changes In Gene Expression and Inflammatory Proteins In Systemic Juvenile Idiopathic Arthritis Patients On Canakinumab Therapy
Background/Purpose: Interleukin (IL)-1β plays a key role in the pathogenesis of systemic juvenile idiopathic arthritis (SJIA). Canakinumab (CAN), a selective, fully human, anti-IL-1β monoclonal antibody,…Abstract Number: 1693 • 2013 ACR/ARHP Annual Meeting
Initial Triple DMARD Therapy Is More Efficient Than Methotrexate Monotherapy In Recent Onset Rheumatoid Arthritis; 1-Year Data Of a Randomized Clinical Trial (tREACH)
Background/Purpose: Recommended treatment for DMARD naïve patients is methotrexate (MTX) with or without glucocorticoids (GCs). Triple DMARD therapy however is not recommended, because well proven…